Spectranetics offers $30M for PAD balloon

Candace Stuart | | Cardiovascular Business | Vascular & Endovascular

Spectranetics will pay $30 million to acquire a drug-coated angioplasty balloon platform from Covidien, if the transaction passes muster with regulators.

The two companies announced an agreement that will transfer the Stellarex platform to Spectranetics to expand Spectranetics’ vascular interventions offerings. The Stellarex drug-coated angioplasty balloon platform is used to treat peripheral artery disease (PAD). In a prospective, multicenter study that enrolled 50 patients with superficial femoral and/or popliteal lesions, the device was shown to be safe with 24-month rates of patency and freedom from clinically driven target lesion revascularization of 80.3 percent and 85.8 percent, respectively.

Based on trial results from 44 patients, the platform is expected to be approved in Europe late this year or early next year. The target date for FDA approval in the U.S. is 2017.

The acquisition is contingent on approval of the Federal Trade Commission and other regulatory agencies. It also will depend on the closure of Medtronic’s acquisition of Covidien, which is expected to be finalized in early 2015.

 

Candace Stuart, Contributor

Related Content

IVUS-guided PCI reduces risks in patients with diabetes
LAAC with Watchman FLX reduces bleeding risks after AFib ablation
Bioresorbable BTK stent superior to ballon angioplasty at 2 years
Shockwave Medical’s IVL technology delivers more positive outcomes for PAD patients
Standing desks fail to lower blood pressure or minimize heart risks—they may even do damage
IVL vs. RA for chronic total occlusion PCI: Key data cardiologists should know

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Radiology Business
What does radiology have to do with climate change?

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."